Seeking Alpha

Study of Intercept liver treatment stopped early due to success

  • A Phase II trial of Intercept Pharmaceuticals' (ICPT) obeticholic acid (OCA) for the treatment of a chronic liver disease called nonalcoholic steatohepatitis (NASH) has been stopped early due to the therapy meeting the primary endpoint of the trial.
  • NASH is caused by excessive fat accumulation in the liver, and can lead to cirrhosis, eventual liver failure and death. No drugs have been approved for the treatment of NASH.
  • "On its current trajectory, the disease is projected to become the leading indication for liver transplant," Intercept says.
  • Shares skyrocket 109%. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs